BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2896212)

  • 1. A flexible peptide spacer increases the efficacy of holoricin anti-T cell immunotoxins.
    Marsh JW; Neville DM
    J Immunol; 1988 May; 140(10):3674-8. PubMed ID: 2896212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
    Ramakrishnan S; Houston LL
    Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
    Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
    J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates.
    Leonard JE; Wang QC; Kaplan NO; Royston I
    Cancer Res; 1985 Nov; 45(11 Pt 1):5263-9. PubMed ID: 3876881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins.
    Stong RC; Youle RJ; Vallera DA
    Cancer Res; 1984 Jul; 44(7):3000-6. PubMed ID: 6372999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen.
    Youle RJ; Uckun FM; Vallera DA; Colombatti M
    J Immunol; 1986 Jan; 136(1):93-8. PubMed ID: 3079613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
    Seon BK
    Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic modulation by anti-CD5 immunotoxins.
    Manske JM; Buchsbaum DJ; Azemove SM; Hanna DE; Vallera DA
    J Immunol; 1986 Jun; 136(12):4721-8. PubMed ID: 3086441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates.
    Pincus SH; Wehrly K; Chesebro B
    J Immunol; 1989 May; 142(9):3070-5. PubMed ID: 2540236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
    Raso V; Ritz J; Basala M; Schlossman SF
    Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of target cells to immunotoxins: possible role of cell-surface antigens.
    Colombatti M; Bron C
    Immunology; 1985 Jun; 55(2):331-8. PubMed ID: 2861156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the selective cytotoxic effects of immunotoxins containing ricin A chain or pokeweed antiviral protein and anti-Thy 1.1 monoclonal antibodies.
    Ramakrishnan S; Houston LL
    Cancer Res; 1984 Jan; 44(1):201-8. PubMed ID: 6140077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.
    Manske JM; Buchsbaum DJ; Vallera DA
    J Immunol; 1989 Mar; 142(5):1755-66. PubMed ID: 2465347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
    Wiels J; Junqua S; Dujardin P; Le Pecq JB; Tursz T
    Cancer Res; 1984 Jan; 44(1):129-33. PubMed ID: 6690030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells.
    Press OW; Martin PJ; Thorpe PE; Vitetta ES
    J Immunol; 1988 Dec; 141(12):4410-7. PubMed ID: 2461993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies].
    Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT
    Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.
    Kernan NA; Knowles RW; Burns MJ; Broxmeyer HE; Lu L; Lee HM; Kawahata RT; Scannon PJ; Dupont B
    J Immunol; 1984 Jul; 133(1):137-46. PubMed ID: 6609971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
    Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
    Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.